Vimentin is an intermediate filament protein whose expression correlates with increased metastatic disease, reduced patient survival and poor prognosis across multiple tumor types. Despite these well-characterized correlations, the molecular role of vimentin in cancer cell motility remains undefined. To approach this, we used an unbiased phosphoproteomics screen in lung cancer cell lines to discover cell motility proteins that show significant changes in phosphorylation upon vimentin depletion. We identified the guanine nucleotide exchange factor (GEF), VAV2, as having the greatest loss of phosphorylation owing to vimentin depletion. Since VAV2 serves as a GEF for the small Rho GTPase Rac1, a key player in cell motility and adhesion, we explored the vimentin-VAV2 pathway as a potential novel regulator of lung cancer cell motility. We show that VAV2 localizes to vimentin-positive focal adhesions (FAs) in lung cancer cells and complexes with vimentin and FA kinase (FAK). Vimentin loss impairs both pY142-VAV2 and downstream pY397-FAK activity showing that vimentin is critical for maintaining VAV2 and FAK activity. Importantly, vimentin depletion reduces the activity of the VAV2 target, Rac1, and a constitutively active Rac1 rescues defects in FAK and cell adhesion when vimentin or VAV2 is compromised. Based upon this data, we propose a model whereby vimentin promotes FAK stabilization through VAV2-mediated Rac1 activation. This model may explain why vimentin expressing metastatic lung cancer cells are more motile and invasive.
INTRODUCTION
Lung cancer is the leading cause of cancer death in the United States.
1 Non-small cell lung cancer, in particular, accounts for about 80% of lung cancer deaths 2 and has a 5-year survival rate of only 15-25%. 3 The poor survival rate results from frequent diagnosis at advanced stages of the disease when metastasis of the primary tumor has already occurred. 2 Metastasis is initiated by genetic and epigenetic factors, leading to the transformation of stationary epithelial cells to migratory cells. 4, 5 This transition, called epithelial mesenchymal transition, 6, 7 is characterized by cell morphology alterations, cytoskeletal reorganization, protein expression changes, enhanced cell adhesion to the extracellular matrix, cell-cell adhesion loss and cell polarity loss. 8 A well-characterized biomarker of epithelial mesenchymal transition is the intermediate filament vimentin. Numerous publications across multiple tumor types show that it is specifically expressed in invasive cell lines and aggressive epithelial-derived tumors, but not expressed in stationary cells. [9] [10] [11] [12] [13] [14] [15] [16] Furthermore, vimentin expression correlates with increased metastasis, reduced survival and poor prognosis for non-small cell lung cancer patients. [17] [18] [19] Despite this clinical correlation, the precise molecular role of vimentin in cancer metastasis is undefined.
Mounting evidence implicates vimentin as a regulator of focal adhesions (FAs) and motility. Vimentin assembly into FAs is a critical determinant of cell adhesion strength 20 and vimentin overexpression enhances FA turnover. 21 Since vimentin enters into FA sites [22] [23] [24] and regulates cell adhesion, a potential molecular link between vimentin and FA kinase (FAK) exists; however this remains uninvestigated. This is further supported by observations that vimentin binds β1 integrin 23 and that the complex formed by FAK, Src, β1 integrin and other proteins is essential for cell migration. 25, 26 Taken together, vimentin has been implicated in cell motility, invasion 27, 28 and lamellipodia formation. 29 While these studies link vimentin expression and function to cell adhesion and migration, the precise mechanisms remain elusive.
Here we identify a novel vimentin-dependent mechanism for cell adhesion and motility. We identified VAV2, a Rac1 guanine nucleotide exchange factor (GEF), whose phosphorylation at Y142 is dependent upon vimentin expression. We use this information to test a vimentin-based model of lung cancer cell adhesion and motility, whereby vimentin promotes VAV2-mediated Rac1 activation at FAs, leading to stabilization of FAK-positive FAs through a potential feedback loop. These data provide a new role for vimentin in mediating lung cancer cell adhesion. Since the initiation of metastasis is accompanied by changes in cell adhesion and motility, these findings may provide insight into the mechanisms driving lung cancer metastasis.
RESULTS
Vimentin regulates lung cancer cell migration, invasion and metastasis Vimentin expression is well-correlated with increased cell motility and invasiveness; however, to verify this correlation in lung cancer cells, H1299 lung cancer cells were transfected with vimentin small interfering RNA (siRNA) (Supplementary Figure S1A) . Vimentindepleted cells showed less cell motility in a wound-healing assay (Supplementary Figure S1B) and significantly less invasion in a standard matrigel Boyden chamber assay (Supplementary Figure  S1C ) compared with control siRNA-transfected cells.
These studies were moved into a xenograft model to determine how vimentin impacts in vivo metastasis. To do this, H460 lung cancer cells stably expressing vimentin small-hairpin RNA (shVIM) and isogenic vector-only (pLKO.1) control cells were generated (Supplementary Figure S2A) . H460 shVIM cells were significantly less invasive in an in vitro matrigel assay compared with pLKO.1 cells (Supplementary Figure S2B) . Cell lines were injected subcutaneously in the flank of nude mice. The primary tumor volume was not significantly different between the H460 control pLKO.1 and shVIM groups (Supplementary Figure S2C) ; however, there was a significant difference in the number of metastatic lung nodules in the shVIM xenograft compared with control ( Supplementary Figures S2D and E) . Furthermore, H460 shVIMinjected mice had significantly fewer micrometastases compared with pLKO.1-injected mice ( Supplementary Figures S2F and G) . Together, these data show that vimentin is important for in vitro lung cancer cell motility and invasion, as well as in vivo metastasis.
Vimentin regulates VAV2 phosphorylation and localizes phosphorylated VAV2 to FAs To investigate how vimentin may regulate cell motility, we performed a phospho-proteomic screen to identify cell motilityrelated proteins that have significant changes in phosphorylation status upon stable-vimentin depletion. H460 shVIM and pLKO.1 lysates were probed with 1318 phospho-specific antibodies and their corresponding non-phosphorylated antibodies (Supplementary Figure S3 ; Supplementary Table S1 ). The ratio of phosphorylated to total protein was calculated for each screened protein. For each protein, this ratio in shVIM cells was plotted against this ratio in isogenic control H460 cells (Figure 1a ). This analysis identified the GEF VAV2 as having the greatest phosphorylation decrease (at Y142) in shVIM cells compared with control. These data were then presented as percent change in phosphorylation and VAV2 showed the greatest percent decrease upon vimentin depletion (Figures 1b and c) . VAV2 is a GEF for the Rho family GTPases Rac1 and cdc42, and is implicated in cell motility, invasion and spreading. [30] [31] [32] [33] Regulation of VAV2 activity occurs by epidermal growth factor receptor (EGFR) phosphorylation of tyrosines 142, 159 and 172. 34 To validate these findings, Western blotting of H460 and H1299 shVIM and pLKO.1 cell lines was performed. Consistent with the screen, vimentin depletion resulted in decreased VAV2 phosphorylation at Y142 in both cell lines (Figure 1d ). Additionally, pY172-VAV2 levels also decreased in vimentin-depleted H1299 cells (Figure 1e ), which provided further evidence that VAV2 activation is reduced upon vimentin loss. When green fluorescent protein-tagged vimentin (hVIM-GFP), which is under the control of a tetracycline-inducible promoter, was expressed in HEK 293 cells; VAV2 Y142 phosphorylation increased (Figure 1f ). Therefore, we have identified a novel downstream GEF whose phosphorylation is dependent upon vimentin expression.
To observe pY142-VAV2 localization in both the pLKO.1 and the shVIM cells, H460 shVIM or pLKO.1 cells were co-stained for vimentin and pY142-VAV2. In pLKO.1 cells, pY142-VAV2 was localized to discrete structures near the periphery of the cell, which resemble FA sites; however, when vimentin is lost, pY142-VAV2 was nearly absent at adhesion sites and its localization became more nuclear (Figures 2a and b) . While there was no significant difference in the size or intensity of the pY142-VAV2 FA sites, the number of sites were significantly reduced upon vimentin loss (Figure 2c ). Since tyrosine 172 of VAV2 is one of the other residues whose phosphorylation is necessary for VAV2 activity, 34 we also analyzed its localization by immunocytochemistry. pY172-VAV2 also appears to be localized to the FAs of H1299 cells (Supplementary Figure S4A) . Since VAV2 is phosphorylated through EGFR signaling, 35 we sought to determine whether vimentin regulates EGFR-mediated VAV2 phosphorylation. We found that vimentin regulated EGFR-mediated phosphorylation of Y142-VAV2 and Y172-VAV2, since shVIM cells had reduced pY142-VAV2 and pY172-VAV2 levels compared with control cells after the addition of EGF (Supplementary Figure S4B) .
To examine the interaction between vimentin and VAV2, we performed a co-immunoprecipitation and show that pY142-VAV2 co-immunoprecipitates with vimentin in total cell lysates. (Figure 2d ). To determine if pY142-VAV2 sites were indeed FA sites, H460 cells were co-stained for pY142-VAV2 and FAK, which serves as a FA marker. These data showed that pY142-VAV2 co-localizes with FAK at the cell periphery ( Figure 2e ) and a co-immunoprecipitation revealed that pY142-VAV2 and FAK associate (Figure 2f ). Together, these data indicate that active VAV2 is a member of the FA complex and vimentin is necessary for proper pY142-VAV2 localization to FAs.
Vimentin loss leads to decreased FAK activation at FA sites Since vimentin is important for proper VAV2 activity and VAV2 localizes to FAK-positive adhesion sites, we tested whether vimentin is required for proper FAK localization. pY397-FAK sites were imaged at the leading edge of the motile isogenic control pLKO.1 and shVIM cells (in H1299 and H460 lung cancer cell lines). In shVIM cells, FAK sites were less numerous, smaller and less intense than in pLKO.1 cells (Figures 3a-f) . Furthermore, total FAK staining showed a similar pattern, in which shVIM cells had reduced total FAK sites (Figure 3g ). In pLKO.1 H1299 and H460 cells, vimentin filaments and squiggles were observed that directly entered into the pY397-FAK sites (Figures 3a,b and e) , suggesting a possible association between pY397-FAK and vimentin. This is consistent with previous observations that vimentin enters into adhesion sites. [22] [23] [24] [36] [37] [38] [39] To confirm that this effect is not specific to FAK and VAV2, we co-stained H460 shVIM and pLKO.1 cells for vimentin and pY418-Src and observed a reduction in the number of pY418-Src-positive FA sites (Supplementary Figure S5) . Taken together, these data indicate that vimentin is important for maintaining FAK-positive FAs and suggest an association between vimentin and FAK.
To further probe vimentin's effect on FAK, Western blotting for pY397-FAK and total FAK in lysates from three different isogenic pairs of shVIM and pLKO.1 lung cancer cell lines was performed. In all cases, pY397-FAK and total FAK levels decreased with vimentin depletion, thereby confirming that vimentin is required for FAK activity and expression (Figure 4a ). This result was confirmed using an independent vimentin small-hairpin RNA clone (Figure 4b ). Furthermore, FAK mRNA levels were unchanged in the isogenic pairs, indicating that this was not likely occurring at the transcriptional level (Figure 4c ). Since total FAK levels were reduced upon vimentin depletion, the effect of vimentin on FAK protein stability was investigated by treating H1299 shVIM and pLKO.1 cells with cycloheximide to inhibit new protein translation. After 12 h of cycloheximide treatment in control cells, FAK protein was still present; however after only 2 h in shVIM cells there was little remaining total FAK (Figure 4d ). Since FAK can be degraded by calpains, 40, 41 we investigated whether vimentin regulates calpain-mediated cleavage of FAK using two calpain inhibitors. In both cases, the calpain inhibitors did not significantly suppress vimentin loss-induced FAK degradation suggesting that FAK is being degraded through an alternative degradation pathway (Supplementary Figure S6) .
To determine if vimentin overexpression can increase pY397-FAK and total FAK expression, hVIM-GFP under the control of a tetracycline-inducible promoter, was introduced into HEK 293 cells. Western blotting showed that both FAK expression and Y397 phosphorylation increased after tetracycline induction of hVIM-GFP ( Figure 4e ). These data show that vimentin overexpression can trigger increased FAK activity and protein expression, and in combination with our previous data suggests that vimentin loss leads to defects in FAK stability.
Based upon our immunofluorescence data showing that vimentin enters into FAK sites, we tested whether vimentin can interact with FAK. A co-immunoprecipitation was performed for endogenous vimentin and FAK from H1299 and an association between the two proteins was observed ( Figure 4f ). Next, we hypothesized that Y397-FAK could be critical for this association since this is the initial FAK autophosphorylation site. To test this, FLAG-tagged phosphomimetic (Y397E) and lossof-phosphorylation (Y397F) FAK mutants were generated. A coimmunoprecipitation between these mutants and vimentin showed that the loss of FAK phosphorylation in the Y397F mutant caused a near complete loss of association with vimentin, while the phosphomimetic mutant still associated with vimentin (Figure 4g ). This finding shows that an intact Y397 FAK site is critical for the association of FAK with vimentin and together these data implicate vimentin as a regulator of FAK activity and stability.
Vimentin-mediated cell adhesion is dependent on FAK activation Since we found that vimentin regulates FAK activity, we explored how this impacts cancer cell adhesion. Cellular attachment and detachment rates of H1299 and H460 pLKO.1 cells and their shVIM isogenic counterparts were measured on fibronectin-coated surfaces. Both shVIM cell lines attached slower than the pLKO.1 cells (Figures 5a and b) indicating attachment defects. Furthermore, both shVIM H1299 and H460 cell lines detached faster after trypsinization than the pLKO.1 cells (Figures 5c and d) . Taken together, these data suggest that shVIM cells have weakened adhesion abilities.
To determine if these adhesion defects are mediated by FAK, H1299 shVIM cells were transfected with constitutively active (CA) Y397E FAK-GFP, wild-type (WT) FAK-GFP or GFP (Supplementary Figure S7A) . Transfected FAK was expressed at a slightly higher level than endogenous FAK (Supplementary Figure S7B) . After trypsin treatment, shVIM cells were less adherent as shown previously, but these defects were nearly completely rescued in WT and Y397E FAK expressing cells (Figures 5e and f) , indicating that while vimentin loss leads to cell adhesion defects, these defects can be restored by overexpressing FAK or expressing a CA-FAK.
VAV2 regulates vimentin-dependent FAK activation and cell adhesion
Since we demonstrated that vimentin regulates both VAV2 and FAK activity and localization, and that pVAV2 localizes to FAK sites, we hypothesized that vimentin regulates FAK via VAV2. To test this, we first determined whether VAV2 depletion impacts pY397-FAK. Transfection of H1299 cells with VAV2 siRNA resulted in decreased pY397-FAK levels compared with cells transfected with control siRNA, with no change in total FAK levels (Figure 6a ), suggesting that VAV2 can regulate FAK activity. We also tested the possibility that FAK impacts VAV2 phosphorylation by determining whether FAK depletion leads to decreased VAV2 phosphorylation. These data show that despite significant siRNA-based FAK depletion, there is no change in VAV2 phosphorylation at Y142 and Y172 indicating that FAK does not impact VAV2 activity directly (Figure 6b) .
To determine if a CA VAV2 can rescue FAK defects in vimentindepleted cells, a GFP-tagged CA VAV2 construct in which the first 184 amino acids are deleted (CA VAV2-GF2) was used. 30, [42] [43] [44] As a negative control, a truncated GFP-tagged dominant negative VAV2 mutant that consists only of the C-terminal SH3, SH2 and SH3 domains was used. Transfection of shVIM cells with CA VAV2-GFP, but not the wild-type VAV2-GFP, rescued the pY397-FAK defects seen in shVIM cells (Figure 6c) . A complementary experiment showed that active VAV2 also rescued the cell adhesion defects observed in vimentin-depleted cells (Figure 6d ). These results show that an active VAV2 rescues both pY397-FAK defects and cell adhesion defects in vimentin-depleted cells.
Vimentin regulates VAV2-mediated Rac1 activation As VAV2 is a GEF for the small Rho GTPases Rac1 and cdc42, 30, 32, 42 we tested whether VAV2 acts through Rac1 and/or cdc42 to regulate FAK. In control and shVIM cells, Rac1 activity had a partial but significant decrease in activity upon vimentin depletion (Figure 7a) . Importantly, CA VAV2, but not dominant negative or wild-type VAV2, could rescue Rac1 activity defects in vimentindepleted cells (Figure 7b ), indicating that activating VAV2 can bypass vimentin function. VAV2 is also a GEF for the small rhoGTPase cdc42; however cdc42 activity was not significantly reduced in shVIM cells compared with control cells (Supplementary Figure S8A) , suggesting that vimentin regulates Rac1 but not cdc42 activity in lung cancer cells.
Next, we tested whether a CA Q61L Rac1 can rescue pY397-FAK levels in vimentin-depleted cells. H1299 shVIM cells were transfected with the Q61L Rac1-active mutant, T17N Rac1-inactive mutant or WT Rac1 45 and pY397-FAK levels were assessed by western blotting. Q61L Rac1, but not WT or T17N Rac1, could rescue pY397-FAK levels (Figure 7c) . A similar experiment was also done with cdc42 but a rescue was not observed (Supplementary Figure S8B) . Along the same lines, confocal imaging was done to test whether expression of the Q61L Rac1 mutant in shVIM cells led to an increase in the number of pY397-FAK sites at the cellular leading edge (Figure 7d ). These data show that CA Q61L Rac1 can induce FA site formation and restore vimentin defects in cell adhesion, which is consistent with the data shown in Figure 7c . Last, we tested whether defects in Rac1 activity would be observed during cell spreading. To do this, serum starved H1299 shVIM and pLKO.1 cells were trypsinized then replated in serum containing media. Peak Rac1 activity was observed at 2 h in pLKO.1 control cells but shVIM cells lacked any observable Rac1 peak (Figure 7e ), suggesting that Rac1 defects are also observed during cell spreading. Taken together, these data further support the model that vimentin signals through VAV2-Rac1 to regulate FAK-based cell adhesion.
DISCUSSION
Though vimentin has been repeatedly shown to correlate with metastatic disease and cell motility, [10] [11] [12] [13] [14] 19 it has been severely understudied as a key regulator of cell motility. Unlike actin and microtubules, which rarely change total expression levels, vimentin is uniquely expressed in invasive cancer cells and other motile cells. Here we describe a novel mechanism for vimentindependent lung cancer cell adhesion. We show that vimentin is required for FAK activity and localization at the cellular leading edge of motile lung cancer cells (Figures 3 and 4) . We propose that vimentin regulates FAK via a VAV2-Rac1 pathway (Figure 8 ) based upon three lines of evidence. First, vimentin depletion causes reduced pVAV2 and pY297-FAK expression, and reduced Rac1 activity. These vimentin-associated defects, along with weakened adhesion, can be rescued with a CA VAV2, showing that VAV2 lies upstream of FAK and Rac1 activity. Interestingly, the dominant negative VAV2 also showed a rescue of pY397-FAK levels but to lesser extent than CA VAV2, which could perhaps be due to incomplete inactivation of VAV2 activity. Second, vimentin is essential for proper pVAV2 localization to FAK-positive adhesion sites and VAV2 associates with vimentin and FAK. We believe that this occurs at adhesion sites, since vimentin directly enters VAV2 and FAK adhesion sites. Interestingly, the FAK Y397 autophosphorylation site appears to be critical for its association with vimentin, since when abolished, the association between FAK and vimentin is lost. Third, CA Rac1 can rescue FAK defects observed in vimentin-depleted cells, which includes restoring pY397-FAK levels and localization at the cellular leading edge. Based upon these data, we propose a model in which vimentin is required for proper VAV2 localization to FAs, where VAV2 serves as a Rac1 GEF, and active Rac1 then promotes FAK-positive FA assembly (Figure 8 ). This is consistent with previous reports showing that Rac1 regulates FAs. [46] [47] [48] [49] Thus, vimentin promotes FA assembly through VAV2-Rac1. Since changes in cell adhesion accompany cell motility, this model provides insight into the mechanism of cell motility.
This model is consistent with the findings of other groups showing that FAs containing vimentin are larger and more stable, 22, 39 and that adhesions are weaker when vimentin is absent. 24 One could speculate that when vimentin is expressed, VAV2 is actively phosphorylated and hence Rac1 is activated. It was previously shown that VAV2 regulates cell invasion and spreading 32, 33 and its activation is linked to cancer invasion and metastasis. 32, 50 VAV2 activation is regulated by EGFR phosphorylation at tyrosines 142, 159 and 172, which is suggested to regulate protein interactions with VAV2 34 to control VAV2 activity. VAV2 and the family member VAV3 are necessary for breast cancer metastasis to the lung. VAV2 and VAV3 knockdown reduced both primary tumorigenesis and lung metastasis. Furthermore, VAV2 and VAV3 overexpression in non-metastatic cells induced metastasis from the primary tumor to the lung. 50 The modest decrease in Rac1 activity upon vimentin depletion in stably adherent cells is likely explained by the fact that VAV2 is For each time point, the ratio of adherent cells to the total cells was calculated. shVIM cells detached faster than pLKO.1 cells. ***P o0.001, ****P o0.0001. (e) The attachment rate was determined for H1299 pLKO.1 cells transfected with GFP and H1299 shVIM cells transfected with GFP, Y397E FAK-GFP or WT FAK-GFP. Expression of Y397E FAK-GFP or overexpression of WT FAK-GFP rescued the attachment defects seen in GFP-transfected shVIM cells. *Po0.05, **P o0.01, ****P o0.0001. (f) The detachment rate was determined for H1299 pLKO.1 cells transfected with GFP and H1299 shVIM cells transfected with GFP, Y397E FAK-GFP or WT FAK-GFP. Expression of Y397E FAK-GFP or overexpression of WT FAK-GFP rescued the adhesion defects seen in GFP-transfected shVIM cells. *P o0.05, **P o0.01, ***P o0.001.
one of many GEFs for Rac1. [51] [52] [53] The remaining Rac1 activity after vimentin depletion could potentially be owing to other Rac1 GEFs. Interestingly, Rac1 but not cdc42 activity is dependent upon vimentin expression. VAV2 is a Rac1 GEF 30, 32, 54 though its role as a cdc42 GEF remains controversial. 44 Rac1 is targeted to FAs and is required for FA complex assembly. 46 ,52 Therefore, we believe that the reduced Rac1 activity results in reduced FAK phosphorylation and improper FAK localization. This is based upon our data showing that a CA Rac1 can rescue vimentin defects and restore normal FAK phosphorylation and localization. As other groups have shown that pFAK is necessary for Rac1 activation, 52, 55, 56 and another group has more specifically found that FAK mediates Rac1 targeting to FAs through tyrosine phosphorylation of the GEF, β PIX, 52 we propose a potential feedback loop between Rac1 and FAK, where increased FAK activity can in turn activate Rac1; however, we do not believe this is through VAV2 as VAV2 activity is unaffected by FAK depletion (Figure 6b) .
Taken together, the work presented here identifies vimentin as a regulator of FA architecture and signaling through VAV2-Rac1 signaling. Since proper functioning of the FAs is required for cell motility and metastasis, this work could lay the groundwork for future studies examining the downstream molecular consequences of vimentin targeting in lung cancer.
MATERIALS AND METHODS

Cell culture
H1299, H460 and H1792 cell lines were grown in Roswell Park memorial institute (RPMI) 1640 media supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin and maintained in a humidified chamber at 37°C with 5% CO 2 . HEK 293 cells were grown in Dulbecco's modified Eagle's media supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. All tissue culture plates and coverslips used for experiments were covered with 5 μg/cm 2 human plasma fibronectin (Millipore, Billerica, MA, USA) diluted in phosphate buffered saline (PBS) and incubated for 30 min at 37°C before cell seeding.
Antibodies
Antibodies against pY397-FAK (Invitrogen, Grand Island, NY, USA), FAK (BD Biosciences, San Jose, CA, USA), GAPDH (Cell Signaling), vimentin (Sigma, St Louis, MO, USA), pY142-VAV2 (Full Moon Biosystems, Sunnyvale, CA, USA), pY172-VAV2 (Abcam, Cambridge, UK), VAV2 (Full Moon Biosystems), GFP (Covance, Princeton, NJ, USA), pY418-Src (Invitrogen) and FLAG (Sigma) were used for Western blotting, immunofluorescence and immunoprecipitation. Horse radish peroxidase-conjugated secondary antibodies (Jackson ImmunoResearch, West Grove, PA, USA) were used for Western blotting. shows that CA VAV2-GFP but not inactive-VAV2-GFP expression rescued the cell adhesion defect seen in GFP-transfected shVIM cells. *P o0.05, ***P o0.001.
Transfections and drug treatments
Lipofectamine 2000 and Plus reagents (Invitrogen) were used to transfect FLAG, WT FAK-FLAG, Y397E FAK-FLAG, Y397F FAK-FLAG, GFP, WT FAK-GFP, Y397E FAK-GFP, WT VAV2-GFP, CA VAV2-GFP, inactive VAV2-GFP, WT Rac1-GFP, Q61L Rac1-GFP, T17N Rac1-GFP, WT cdc42-GFP, Q61L cdc42-GFP and T17N cdc42-GFP constructs according to the Invitrogen supplied protocol. The RevTet-On system (Clontech, Mountain View, CA, USA), which includes pRevTRE carrying the human vimentin gene and pRevTet-On was used. . The shVIM sequence is 5′-TTGAACTGGTG TTGATGGCG-3′ and the shVIM clone 2 sequence is 5′-AATAGTGTCTTGG TAGTTAGC-3′. To produce the virus, HEK 293T cells were transfected with the small-hairpin RNA and helper plasmids (pHRCMV8.2ΔR and CMV-VSVG) using LT1 transfection reagent (Mirius, Madison, WI, USA). To harvest the lentiviral stock, the media was centrifuged at 250 g for 5 min then filtered through a syringe. Cells were infected with a 1:4 dilution of lentivirus in complete media containing 8 μg/ml polybrene. The next day, the media was changed to complete media containing 2 μg/ml puromycin. For the cyclohexamide experiment, H1299 cells were treated with 20 μg/ml cyclohexamide (Sigma) in complete RPMI media.
Adhesion assays
For the detachment assays, cells were plated at 1 × 10 5 to 1.5 × 10 5 cells per well in a 12-well plate. After 24 h, each well was trypsinized for lengths of time ranging from 0 to 5 min. At each time point, a volume of complete RPMI media that is equivalent to twice the volume of trypsin was added to the well. The non-adherent cell containing media was aspirated off and each well was washed with 1 × PBS. The remaining adherent cells were trypsinized and counted. The number of adherent cells in each well was normalized to the total number of cells (0 time point). For the attachment assays, the concentration of each cell line after collection by trypsinization was equalized to 5 × 10 5 cells/ml. Cells (1 ml) were added to each well of a 12-well plate and incubated for varying lengths of time ranging from 10 to 90 min. At each time point, the non-adherent cells were aspirated off. The adherent cells were washed gently with PBS, trypsinized and then counted.
Western blotting
Cells were harvested and lysed in cold TNES buffer (50 mM Tris pH 7.5, 100 mM NaCl, 2 mM EDTA, 1% Nonidet P-40, 1 × Roche Complete Protease Inhibitors, Roche, Basel, Switzerland, 10 mM NaF, 1 mM NaVO 4 , 2 mM sodium pyrophosphate and 2 mM β-glycerophosphate). Protein concentrations were determined using a protein assay kit (Pierce, Rockford, IL, USA). Equal protein concentrations of whole cell lysate were solubilized in SDS sample buffer, separated on a 10% SDS-polyacrylamide gel, and transferred to a methanol soaked polyvinyalide diflouride membrane, which was then blocked with 10% milk in 1 × Tris-Buffered Saline with Tween (TBST). Primary antibody, diluted in 5% milk in TBST, was added to the membrane while rocking overnight at 4°C. After three TBST washes, the appropriate horse radish peroxidase-conjugated secondary antibody diluted in 5% milk in TBST was added to the blot for 1 h at room temperature. After three more TBST washes, proteins were visualized using a chemiluminescent substrate (Denville, South Plainfield, NJ, USA).
Quantitative real-time PCR Total RNA was isolated using an RNeasy Mini Kit (Qiagen) then reverse transcribed with M-MLV reverse transcriptase (Invitrogen). The complementary DNA product was amplified using sequence specific primers to FAK (forward, 5ʹ-TGGTGAAAGCTGTCATCGAG-3ʹ; reverse, 5ʹ-TCATCCA CAGTGGCCAATAA-3ʹ ) and analyzed by real-time PCR using SYBR green detection. Reactions (25 μl) contained 1 μl DNA, 0.2 μM of each primer and 12.5 μl IQ SYBR Green Supermix (Bio-Rad, Hercules, CA, USA). The following PCR protocol was used: 3 min hot start at 95°C followed by cycles of 95°C, 10 s; 55°C 60 s. Melt curve analysis verified a single product. Relative RNA quantities were calculated then standardized to levels of 18S ribosomal RNA.
Immunofluorescence
Cells were fixed on 1.5 mm glass coverslips with PHEMO buffer (68 mM PIPES, 25 mM HEPES, 15 mM ethylene glycol tetraacetic acid, 3 mM MgCl 2 , Figure 8 . Vimentin regulates FAK activity through a VAV2-Rac1 dependent pathway. In the presence of vimentin, VAV2 is phosphorylated at Y142 and localizes to the focal adhesions with FAK and vimentin. Phosphorylated VAV2 activates Rac1, which allows FAK activation at the focal adhesions.
10% dimethylsulfoxide) plus 3.7% formaldehyde, 0.05% glutaraldehyde and 0.5% Triton X-100 for 10 min at room temperature. After three 5 min washes with PBS, the coverslips were blocked with 10% normal goat serum for 1 h at room temperature. Primary antibodies were diluted in 5% normal goat serum and added to the coverslips overnight at 4°C. After three PBS washes, the coverslips were incubated for 1 h at room temperature with a fluorophore-conjugated secondary antibody diluted in 5% normal goat serum. After three PBS washes, the coverslips were incubated with 350 nM 4,6-diamidino-2-phenylindole stain diluted in 1 × PBS for 10 min at room temperature. The coverslips were mounted on glass slides using Prolong gold mounting medium (Invitrogen). The slides were imaged using a Zeiss LSM 510 META confocal microscope (Zeiss, Thornwood, NY, USA) with a 100 × oil Plan-Apo objective (numerical aperture = 1.46). The images were processed using ZEN 2009 software (Zeiss, Oberkochen, Germany). A Nikon N-SIM microscope (Nikon, Tokyo, Japan) housed within the Emory Integrated Cellular Imaging Core was utilized to acquire super-resolution images of vimentin directly entering FAs. Images were acquired using a 100 × 1.49 numerical aperture oil objective. All images within an experiment were taken under identical settings. Intensity levels were adjusted equally on all samples within an experiment.
Immunofluorescence image quantification
To assess FA site size and intensity, images were analyzed in ImageJ/Fiji. A 100 µm 2 rectangle was used as a region-of-interest at the leading edge of cells. Pixels within this region-of-interest were then thresholded to remove background and the same threshold was used for all samples stained with the same antibody. The 'Analyze Particle' function was then implemented to detect objects. All objects less than 0.5 µm 2 were then removed using a size filter. The intensities and size of the remaining objects were then quantified and imported into Excel.
Co-immunoprecipitation
Cells were harvested and lysed in NP-40 lysis buffer (50 mM Tris pH 7.4, 50 mM NaCl, 0.1% Triton X-100, 1% NP-40) plus 1 × Roche Complete Protease Inhibitors (Roche), 10 mM NaF, 1 mM NaVO 4 , 2 mM sodium pyrophosphate and 2 mM β-glycerophosphate. For co-immunoprecipitations involving vimentin, total lysate was used. For all other coimmunoprecipitations, lysate was centrifuged at 14,000 g at 4°C for 10 min. Primary antibody (10 μg) was incubated with 500 μg of protein at 4°C overnight while rotating. Each sample was incubated with 50 μl of Dynabeads (Invitrogen) for 1 h at 4°C while rotating. After three 20 min washes with NP-40 lysis buffer, the protein-antibody complex was eluted from the beads in 2 × Laemmli buffer at 100°C for 10 min.
Phosphorylation screen H460 pLKO.1 and shVIM cell lysates were analyzed using the Phospho Explorer Antibody Array (Full Moon Biosystems), which is a microarray containing 1318 phospho-specific antibodies spotted on a coated glass slide in duplicate. Cell lysates were given to Full Moon Biosystems for processing and analysis. Lysates were labeled with biotin then bound to the array's antibodies. The phosphorylated protein in each sample was detected using Cy3-streptavidin. The array was scanned with an Axon GenePix scanner (Molecular Devices, Sunnyvale, CA, USA) to measure phosphorylation levels of individual proteins in each sample. The ratio of phosphorylated to total protein was calculated for both pLKO.1 and shVIM cells and reported as a fold change upon vimentin loss. The percent change in phosphorylation upon vimentin depletion was calculated as a ratio of phosphorylated/total protein in shVIM cells to phosphorylated/ total protein in pLKO.1 cells.
Rac1 activation assays
The G-LISA rac1 luminescence-based activation assay kit (Cytoskeleton, Denver, CO, USA) was used to measure rac1 activity in stably adherent cells. The cells were lysed in the supplied lysis buffer. Lysates were diluted to 1 μg/μl then processed according to the supplied protocol. Readings were obtained using spectraMax luminometer (Molecular Devices). For the timecourse experiment on trypsinized cells that were replated, we used a Rac1 activation pull-down kit (Cytoskeleton). Cells were lysed in the supplied lysis buffer then diluted to 1.5 μg/ μl and processed according to the supplied protocol. The pull-down products were analyzed by western blotting using a Rac1 antibody from BD Biosciences.
Statistical analysis
P-values of significance were obtained using one-or two-way analysis of variance followed by a multiple comparison test. In the case of the xenograft and quantitative real-time-PCR studies, a Student's t-test was employed.
